Drug Information

Drug General Information
Drug ID
D0M5JA
Former ID
DIB017002
Drug Name
Lumiliximab
Synonyms
Gomiliximab; IDEC-152; SI-3401; ST-152; PRIMATIZED anti-CD23 antibody, IDEC
Drug Type
Antibody
Indication Leukemia [ICD9: 208.9; ICD10:C90-C95] Phase 2 [521906]
Company
IDEC Pharmaceuticals Corp; Biogen Idec
CAS Number
CAS 357613-86-6
Target and Pathway
Target(s) Fc-epsilon-RII (CD23) Target Info [527784]
KEGG Pathway Hematopoietic cell lineage
Epstein-Barr virus infection
NetPath Pathway IL-7 Signaling Pathway
IL3 Signaling Pathway
IL4 Signaling Pathway
Pathway Interaction Database IL4-mediated signaling events
Reactome NOTCH2 intracellular domain regulates transcription
WikiPathways Human Complement System
Signaling by NOTCH2
References
Ref 521906ClinicalTrials.gov (NCT00391066) Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health.
Ref 527784Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.